Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. For more information, please visit www.harpoontx.com.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $201.25M
Founded date: 2015
Investors 8
Funding Rounds 3
| Date | Series | Amount | Investors |
| 02.01.2019 | IPO | $86.25M | - |
| 12.11.2018 | Series C | $70M | - |
| 25.05.2017 | Series B | $45M | Arix Biosc... |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Jo | Viney | Board of D... | linkedin.c... | - | - |
Mentions in press and media 25
| Date | Title | Description | Source |
| 11.05.2023 | Harpoon Therapeutics Reports First Quarter 2023 Financial Re... | /EIN News/ -- Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and ... | einpresswi... |
| 04.10.2022 | A top Wall Street analyst names 3 tiny biotechs that look li... | The British pharma giant AstraZeneca has quietly been working on gene-editing research over the past... | businessin... |
| 11.06.2021 | ARIX BIOSCIENCE PLC Clinical portfolio update | Arix Bioscience PLC (ARIX) Clinical portfolio update 11-Jun-2021 / 13:05 GMT/BST Dissemination of a ... | marketscre... |
| 23.02.2021 | Harpoon Therapeutics : Corporate Presentation – February 202... | Spearheading Immunotherapies INVESTOR PRESENTATION FEBRUARY 2021 Forward-looking Statements This pre... | marketscre... |
| 27.04.2020 | Regeneron/Sanofi PD-1 trial halted for significant ef... | → It’s a good news, bad news day for Sanofi and Regeneron. On the same morning their joint Kevzar... | endpts.com... |
| 22.02.2019 | MPM Capital raises $400M in seventh venture fund | “Over two decades of investing, MPM has developed long-standing and strategic partners with academia... | medcitynew... |
| 02.01.2019 | Harpoon Therapeutics files for $86.25M IPO | According to the filing, the company is seeking to raise $86.25 million in the IPO. Citigroup and Le... | medcitynew... |
| 13.11.2018 | Harpoon Therapeutics raises $70M Series C for T-cell engager... | The South San Francisco, California-based company is developing T-cell engagers using its platform, ... | medcitynew... |
| 12.11.2018 | Harpoon $70M Series C Funding Round | Harpoon, a South San Francisco, CA-based clinical-stage immunotherapy company developing a novel cla... | finsmes.co... |
| 12.11.2018 | Harpoon Therapeutics Announces Closing of $70M Series C Fina... | - | mpmcapital... |
Show more